TOC
Pharm Exec talks to the newly appointed leaders of the industry's most influential advocacy organizations.
Patrick Clinton
Editor-in-Chief
Jill Wechsler
Washington Correspondent
Pharm Exec talks to the newly appointed leaders of the industry's most influential advocacy organizations.
Billy Tauzin
PhRMA's new president is tasked with making politically-charged issues non-partisan, and positioning the industry on the sides of patients and doctors.
James Greenwood
As president of BIO, Greenwood plans to employ three secret tools of advocacy: the truth, the truth and the truth.
Features
AIDS in Africa
The Road Forward
Joanna Breitstein
Senior Editor
The world has its eyes—and hopes—set on pharma's treatment models to scale up efforts to fight the AIDS epidemic. Will they be ready? The second in a two-part series.
Counterfeiting
More than Just a Pretty Color
David R. Schoneker
Colorcon
On-tablet technologies go further than RFID because they ensure the integrity and safety of pills throughout the supply chain, and into patients' mouths.
Clinical Trials
Transparent Trade-Offs
Bob Korsan and Kevin Dykstra
Pharmsight
William Pullman, MD
Aventis Pharmaceuticals
The market judges drugs on more than just efficacy. Clinical Utility Indices measure these considerations throughout the development process, before it's too late.
News & Analysis
Leading Indicators
News
Government cracks down on conflicts of interest » FDA Commissioner Lester Crawford to focus on drug safety » Pharma's sales growing slower » SEC rules jeopardize vaccine stockpiles » FDA establishes drug safety panel » FDA OKs Aspen's AIDS drug for Africa.
Data
Pharma's bad rap just got worse » Scripts for SSRIs slowed before FDA's proposed black box warning.
Thought Leaders
Marlene Bobka, VP of FOI Services, on the intelligence to be harvested from the Freedom of Information Act.
Washington Report
Putting the Medicare benefit into practice means pharma has to tackle some thorny issues.
Jill Wechsler
Global Report
European regulators consider new safety systems in response to Vioxx.
Sarah Houlton
Leadership
Just because you're paranoid, it doesn't mean that they're not after you.
Sander A. Flaum
Flaum Partners
Legal Forum
India's new patent law threatens the country's generic ARV supply, a vital part of AIDS treatment.
Nagendra Setty
Jones Day
Strategy & Tactics
Direct to Consumer
Consumers make decisions with their pocketbooks, so why not partner with the payers?
Lisa B. Bair
The Hobart Group
Marketing to Professionals
Forget about outsourcing marketing materials—for some companies, real efficiencies are found in farming out the whole department.
Rich Levy
Ferguson
Alternative Media
Reaching doctors through e-mail is easier than you might think.
Sales Management
Allocating sales calls based on doctors' past prescribing behaviors will not improve sales force productivity.
S. Kent Stephan
Princeton Brand Econometrics
Public Relations
Disease awareness days are effective at improving knowledge about conditions—but only if they get noticed.
Megan Svenson
Marina Maher Communications
Insights
From the Editor
We have lots of solutions to drug safety—just not to the right problems.
Patrick Clinton
Editor-in-Chief
Back Page
States are in front of federal government in codifying compliance and disclosure of marketing spend.
Noah Shannon and Judith Braun-Davis
Polaris Management Partners
Resources
People Update
Calendar of Events
Advertisers Index
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
